前列腺癌组织DLL3、ATF6的表达及其与临床病理参数和预后的关系-东南大学学报医学版

前列腺癌组织DLL3、ATF6的表达及其与临床病理参数和预后的关系

单位：1. 沧州市人民医院生殖医学科, 河北沧州 061000;
2. 沧州市人民医院泌尿外科, 河北沧州 061000

分类号：R737.25

出版年·卷·期（页码）：2025·44·第四期（563-568）

摘要：

目的:探究前列腺癌组织delta-样配体3(DLL3)、激活转录因子6(ATF6)的表达及其与临床病理参数和预后的关系。方法:选取2022年2月至2023年5月本院收治的92例前列腺癌患者作为研究对象。采用免疫组织化学法检测前列腺癌组织和癌旁组织DLL3、ATF6的表达情况;对患者进行为期1年的随访,详细记录其随访结果,根据生存情况将患者分为死亡组与生存组;Cox多因素回归分析前列腺癌患者预后的影响因素;Kaplan-Meier法分析前列腺癌组织DLL3、ATF6表达情况与患者预后的关系。结果:DLL3在前列腺癌组织中阳性表达占78.26%,ATF6阳性表达占69.57%;DLL3在癌旁正常组织中阳性表达占18.48%,ATF6阳性表达占16.30%。DLL3、ATF6表达水平在癌组织与癌旁正常组织中差异具有统计学意义(P<0.05)。DLL3、ATF6在发生肌层浸润、TNM分期Ⅲ＋Ⅳ期和发生远处转移的癌组织中具有更高的阳性表达率(P<0.05);前列腺癌患者的预后独立危险因素为肌层浸润、TNM分期Ⅲ＋Ⅳ期、远处转移、DLL3(阳性)和ATF6(阳性)(P<0.05);前列腺癌组织DLL3阴性表达患者1年生存率(90.00%,18/20)高于DLL3阳性表达患者(65.28%,47/72)(χ²=4.323,P=0.038);前列腺癌组织ATF6阴性表达患者1年生存率(89.29%,25/28)高于ATF6阳性表达患者(62.50%,40/64)(χ²=6.275,P=0.012)。结论:DLL3、ATF6表达水平升高会造成前列腺癌患者病情恶化及预后情况较差。

Objective: To investigate the relationship between the expression of delta like ligand 3(DLL3) and activated transcription factor 6(ATF6) in prostate cancer tissue and clinical pathological parameters and prognosis. Methods: From February 2022 to May 2023, 92 prostate cancer patients admitted to our hospital were regarded as subjects. Immunohistochemistry was applied to detect the expression of DLL3 and ATF6 in prostate cancer tissues and adjacent tissues. Follow up the patients for a period of 1 year, their follow-up results were recorded in detail, and patients were divided into a death group and a survival group based on their survival status. Cox multivariate regression was applied to analyze the factors influencing the prognosis of prostate cancer patients. The relationship between the expression of DLL3 and ATF6 in prostate cancer tissue and patient prognosis was analyzed using Kaplan-Meier method. Results: DLL3 was positively expressed in 78.26% of prostate cancer tissues, while ATF6 was positively expressed in 69.57%. DLL3 was positively expressed in 18.48% of normal tissues adjacent to the cancer, and ATF6 was positively expressed in 16.30%. The expression levels of the two were obviously different between cancer tissues and normal tissues adjacent to cancer(P<0.05). DLL3 and ATF6 had higher positive expression rates in cancer tissues with muscle infiltration, TNM stage Ⅲ＋Ⅳ, and distant metastasis(P<0.05). The independent prognostic risk factors for prostate cancer patients included muscle infiltration, TNM stage Ⅲ＋Ⅳ, distant metastasis, DLL3(positive), and ATF6(positive)(P<0.05). The one-year survival rate of patients with negative expression of DLL3 in prostate cancer tissue(90.00%, 18/20) was higher than that of patients with positive expression of DLL3(65.28%, 47/72)(χ²=4.323, P=0.038). The one-year survival rate of patients with negative expression of ATF6 in prostate cancer tissue(89.29%, 25/28) was higher than that of patients with positive expression of ATF6(62.50%, 40/64)(χ²=6.275, P=0.012). Conclusion: Elevated expression levels of DLL3 and ATF6 can lead to worsening of the condition and poor prognosis in prostate cancer patients.

参考文献：

[1] 周金才,居峰,倪颖,等.前列腺健康指数在不同tPSA区间段诊断前列腺癌的临床价值研究[J].现代医学,2023,51(7):918-922.
[2] SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer statistics,2022[J].CA Cancer J Clin,2022,72(1):7-33.
[3] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[4] REBELLO R,OING C,KNUDSEN K,et al.Prostate cancer[J].Nat Rev Dis Primers,2021,7(2):9-17.
[5] SHIRASAWA M,YOSHIDA T,SHIRAISHI K,et al.Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer[J].Br J Cancer,2023,129(12):2003-2013.
[6] AJKUNIC A,SAYAR E,ROUDIER M P,et al.Assessment of TROP2,CEACAM5 and DLL3 in metastatic prostate cancer:expression landscape and molecular correlates[J].NPJ Precis Oncol,2024,8(1):104-112.
[7] 王优,肖玲,尹青桥,等.miR-203a-3p靶向调控ATF6抑制高糖诱导的大鼠系膜细胞凋亡及其机制[J].中国老年学杂志,2024,44(14):3525-3530.
[8] MACKE A J,PACHIKOV A N,DIVITA T E,et al.Targeting the ATF6-mediated ER stress response and autophagy blocks integrin-driven prostate cancer progression[J].Mol Cancer Res,2023,21(9):958-974.
[9] 何立儒,李春媚,刘明,等.中国前列腺癌放射治疗指南(2020年版)[J].中华肿瘤防治杂志,2021,28(5):323-337.
[10] CARLSSON S V,VICKERS A J.Screening for prostate cancer[J].Med Clin North Am,2020,104(6):1051-1062.
[11] SEKHOACHA M,RIET K,MOTLOUNG P,et al.Prostate cancer review:genetics,diagnosis,treatment options,and alternative approaches[J].Molecules,2022,27(17):5730-5738.
[12] 姚云峰,曹春.靶向DLL3治疗小细胞肺癌的研究进展[J].中国肿瘤生物治疗杂志,2024,31(7):733-737.
[13] ZHANG H,YANG Y,LI X,et al.Targeting the Notch signaling pathway and the Notch ligand,DLL3,in small cell lung cancer[J].Biomed Pharmacother,2023,159(32):114248-114255.
[14] 李雨璇,于莉娜,张韦洋,等.DLL3通过调节MAPK通路促进前列腺癌进展[J].中国病理生理杂志,2023,39(12):2165-2175.
[15] WANG J,ZHANG K,LIU Z,et al.Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer:a retrospective study[J].Medicine(Baltimore),2018,97(51):e13442-e13451.
[16] MATSUO K,TANIGUCHI K,HAMAMOTO H,et al.Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy[J].Cancer Sci,2019,110(10):3122-3131.
[17] KOSHKIN V S,GARCIA J A,REYNOLDS J,et al.Transcriptomic and protein analysis of small-cell bladder cancer(SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target[J].Clin Cancer Res,2019,25(1):210-221.
[18] HAMAMOTO H,MAEMURA K,MATSUO K,et al.Delta-like 3 is silenced by HBx via histone acetylation in HBV-associated HCCs[J].Sci Rep,2018,8(1):4842.
[19] SPINO M,KURZ S C,CHIRIBOGA L,et al.Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase-mutant glioma[J].Clin Cancer Res,2019,25(4):1261-1271.
[20] 张信,梁文宝,赵恒,等.EDEM1通过稳定ATF6促进颅内动脉瘤发展的作用研究[J].河北医学,2024,30(5):720-724.
[21] LIU J,XIAO M,LI J,et al.Activation of UPR signaling pathway is associated with the malignant progression and poor prognosis in prostate cancer[J].Prostate,2017,77(3):274-281.
[22] 刘恒川,杨宗珂,刘清源,等.ATF6通过Hippo-YAP信号通路促进前列腺癌PC3细胞的增殖、迁移和侵袭[J].陆军军医大学学报,2023,45(1):29-37.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录